← All trials
NCT01910259
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2014
- Primary completion
- Jul 1, 2018
- Completion date
- Jul 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 445
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- University of LondonLead sponsor
- University of EdinburghOverall official - principal investigator
- University of LondonOverall official - principal investigator
- Medical Research CouncilCollaborator
- University of EdinburghCollaborator
- Keele UniversityCollaborator
- University of LeedsCollaborator
- University of WarwickCollaborator
- University of LondonCollaborator
- Sheffield Hallam UniversityCollaborator
- MS SocietyCollaborator
- National Institute for Health Research, United KingdomCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.